KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Accounts Payables (2017 - 2025)

Bionano Genomics' Accounts Payables history spans 7 years, with the latest figure at $6.0 million for Q3 2025.

  • For Q3 2025, Accounts Payables fell 31.15% year-over-year to $6.0 million; the TTM value through Sep 2025 reached $6.0 million, down 31.15%, while the annual FY2024 figure was $7.0 million, 32.95% down from the prior year.
  • Accounts Payables for Q3 2025 was $6.0 million at Bionano Genomics, down from $6.2 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $15.8 million in Q1 2023 and bottomed at $2.2 million in Q1 2021.
  • The 5-year median for Accounts Payables is $8.7 million (2024), against an average of $8.8 million.
  • The largest annual shift saw Accounts Payables skyrocketed 267.54% in 2021 before it plummeted 43.39% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $10.8 million in 2021, then rose by 16.39% to $12.5 million in 2022, then fell by 17.15% to $10.4 million in 2023, then plummeted by 32.95% to $7.0 million in 2024, then fell by 13.96% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Accounts Payables are $6.0 million (Q3 2025), $6.2 million (Q2 2025), and $6.6 million (Q1 2025).